Skip to main content

ERRATUM article

Front. Oncol., 29 December 2021
Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers
Volume 11 - 2021 | https://doi.org/10.3389/fonc.2021.832786
This article is part of the Research Topic Epigenetic Dysregulation in GI Cancers View all 8 articles

Erratum: Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Carcinoma by Inhibiting IL-6 Signaling Pathway

This article is an erratum on:

  1. Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Carcinoma by Inhibiting IL-6 Signaling Pathway

    1. Read original article
Frontiers Production Office* Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

An Erratum on
Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Carcinoma by Inhibiting IL-6 Signaling Pathway

By Lu Y, Xin D, Guan L, Xu M, Yang Y, Chen Y, Yang Y, Wang-Gillam A, Wang L, Zong S and Wang F (2021). Front. Oncol. 11:762523. doi: 10.3389/fonc.2021.762523

Due to a production error, the title was incorrectly written as “Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Catrcinoma by Inhibiting IL-6 Signaling Pathway”. The correct title is “Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Carcinoma by Inhibiting IL-6 Signaling Pathway”.

The publisher apologizes for this mistake.

The original version of this article has been updated.

Keywords: metformin, PD-L1, anti-PD-1 antibody, esophageal squamous cell carcinoma, IL-6/JAK2/STAT3 signaling pathway

Citation: Frontiers Production Office (2021) Erratum: Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Carcinoma by Inhibiting IL-6 Signaling Pathway. Front. Oncol. 11:832786. doi: 10.3389/fonc.2021.832786

Received: 10 December 2021; Accepted: 10 December 2021;
Published: 29 December 2021.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2021 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.